Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gerresheimer AGGRRMY 60 5-Year Yield-on-Cost % is 0.00 as of Jul. 27, 2026. GuruFocus rates GRRMY with a GF Score™ of 60/100 and a GF Value™ of $26.57 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 324 Medical Devices & Instruments companies, Gerresheimer AG ranks worse than 308641.67% on this metric.
Gerresheimer AG's yield on cost for the quarter that ended in Nov. 2025 was 0.00.
The historical rank and industry rank for Gerresheimer AG's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Gerresheimer AG's highest Yield on Cost was 0.24. The lowest was 0.01. And the median was 0.13.
GRRMY's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.48 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Gerresheimer AG (OTCPK:GRRMY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Gerresheimer AG 5-Year Yield-on-Cost % Related Terms
GRRMY vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's 5-Year Yield-on-Cost % falls into.
Gerresheimer AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Gerresheimer AG is calculated as
Gerresheimer AG (GRRMY) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gerresheimer AG and its competitors. Over the past decade, Gerresheimer AG's 5-Year Yield-on-Cost % has ranged from 0.01 to 0.24. According to the industry distribution chart, Gerresheimer AG ranks #999999 out of 324 companies in the Medical Devices & Instruments industry.
Is Gerresheimer AG's 5-Year Yield-on-Cost % too high?
Gerresheimer AG's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.24. Based on the distribution chart, Gerresheimer AG ranks #999999 out of 324 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gerresheimer AG has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #999999 out of 324 companies for 5-Year Yield-on-Cost %. This places Gerresheimer AG in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.48. Historically, Gerresheimer AG's own 5-Year Yield-on-Cost % has ranged from 0.01 to 0.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.48, based on 324 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gerresheimer AG and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gerresheimer AG's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (GRRMY) is currently considered Possible Value Trap. The stock's GF Value™ is $26.57, compared to a current price of $7.90 — trading 70.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Gerresheimer AG's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Gerresheimer AG (GRRMY), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (GRRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of $7.90 is trading 70.3% below its estimated GF Value™ of $26.57.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for GRRMY:
5-Year Yield-on-Cost %: 0.00
GF Value™: $26.57 vs. price of $7.90 (70.3% below fair value)
No single metric tells the full story. See the GRRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
60GF Score
Get the complete analysis for GRRMY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRRMY has been successfully added to your 
